Primary Sclerosing Cholangitis Market Report and Forecast 2025-2034

Primary Sclerosing Cholangitis Market Outlook

The primary sclerosing cholangitis market size in the 7 major markets was valued at USD 151.07 million in 2024, driven by the rising technical advancements in drug development. The market is expected to grow at a CAGR of 7.60% during the forecast period of 2025-2034, with the values likely to rise from USD 162.6 million in 2025 to USD 292.1 million by 2034.

Primary Sclerosing Cholangitis: Introduction

Primary sclerosis cholangitis is a chronic liver condition where the bile ducts get inflamed, scarred, and eventually becomes narrow and blocked. The disease progresses slowly and eventually leads to liver failure. Common symptoms include itchy area, abdomen pain, jaundice, diarrhea or fatigue and fever. It is caused by an immune system reaction to a toxin or infection. Liver function blood tests, bile duct MRIs and CT scans are used to diagnose the condition in patients.

Primary Sclerosing Cholangitis Market Analysis

The primary sclerosing cholangitis market demand is poised to rise with increasing frequency of drug development demonstrating positive results in clinical trials. In June 2023, Chemomab Therapeutics Ltd. presented positive data supporting CM-101, a CCL24-neutralizing antibody, as a driver of disease pathology in detecting primary sclerosing cholangitis. In addition, Galmed Pharmaceuticals Ltd. also launched a clinical program to evaluate its lead compound, Aramchol meglumine, for the treatment of PSC. This also indicates the rising trend of pharmaceutical companies taking part in expanding their product portfolios.

As a part of further investigation, researchers have also been working on developing PSC-IBD (inflammatory bowel disease) combined medications. This is because the pathogenesis and treatment for both is similar. Potential candidate drugs, such as those that target modulation of bile acids, inflammation, fibrosis, and gut dysbiosis, have been developed for both. Bile acids modulators such as Obeticholic acid, Cilofexor and inflammation modulators like Cenicriviroc, Vedolizumab, along with statins, are some key areas of investigation. The rising investment and research and development in the market is anticipated to aid the market growth further.

The rising prevalence of minimally invasive procedures, owing to benefits like faster recovery and lesser complications, is expected to boost the primary sclerosing cholangitis market growth in the forecast period.

Primary Sclerosing Cholangitis Market Segmentation

Market Breakup by Type

• Classic PSC

• Small-duct PSC

• PSC Associated with Autoimmune Hepatitis

Market Breakup by Treatment

• Ursodeoxycholic Acid

• Obeticholic Acid

• Methotrexate

• Corticosteroids

• Others

Market Breakup by Drug Type

• Antihistamines

• Cholestyramine

• Antibacterials

• Opioid Antagonists

• Colestipol

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

Primary Sclerosing Cholangitis Market Overview

Owing to the rising primary sclerosing cholangitis market demand, the United States has made significant efforts to offer a diverse of effective treatment alternative to the patients. The presence of prominent pharmaceutical and healthcare companies, as well as research institutions has fuelled the market growth.

To combat the increasing liver associated diseases, countries like Japan, China, and India have been working on improving the medical and research infrastructure of the region. The government of India has launched a ‘Illness to Wellness’ campaign in August 2023. This national awareness program promoted healthy living with balanced diet, along with good eating habits. Such programs are expected to contribute significantly to the rising primary sclerosing cholangitis market share in the coming years.

Europe is another significant player in the market with a well-developed research infrastructure that aids in development and testing of new technologies and drugs. The World Health Organization launched “One life, one liver” to boost awareness on liver health. Such initiatives and campaigns are also anticipated to boost the market value in the forecast period as well.

Primary Sclerosing Cholangitis Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Allergan

• Glenmark Pharmaceutical

• Merck & Co

• Sanofi

• Novatris AG

• Baxter

• Pfizer Inc.

• Takeda Pharmaceutical

• F. Hoffmann-La Roche Ltd

• Abbott

• Mylan N.V.

• HighTide Inc.

• Sirnaomics

• Acorda Therapeutics

• NGM Biopharmaceuticals

• Sandoz International GmbH

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report